Saturday 17 October 2026
Export ELOX’s income statement to Excel — free account
Senesco Technologies Inc.
ELOX Healthcare Biotechnology
Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
13.03
0.67
−4.89%
Follow ELOX
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.00% | 0.00% | 78.27% | (89.91%) | |
| (336.49%) | 0.00% | (141.35%) | (34.15%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 135.09% | (25.54%) | |
Free Cash Flow per Share |
(17.32) | — | (1.83) | (1.59) | |
Free Cash Flow |
(6.01) | — | (8.01) | (10.79) | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 659.51% | (9.96%) | |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Operating CF/Net income |
0.60 | — | 0.78 | 0.91 | |
Depreciation/Fixed assets |
0.00 | — | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
(17.32) | — | (1.83) | (1.59) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates